Bio-Gene Technology Limited (BGT:ASX) Investor Relations Material

Overview

BlackRock Inc. has recently launched their BlackRock Floating Rate Income Trust, which operates as a close-ended fixed income mutual fund. The fund, which is administered by BlackRock Advisors, LLC and BlackRock Financial Management, Inc., concentrates on the fixed income markets worldwide, particularly in the United States. The company utilizes a diverse approach by investing in bonds from companies spanning various sectors. The average effective duration of the portfolio is approximately 1.5 years and primarily consists of corporate bonds. The trust was previously named BlackRock Global Floating Rate Income Trust and was established on August 30, 2004, domiciled in the United States.

Frequently Asked Questions

What is Bio-Gene Technology Limited's ticker?

Bio-Gene Technology Limited's ticker is BGT

What exchange is Bio-Gene Technology Limited traded on?

The company's shares trade on the ASX stock exchange

Where are Bio-Gene Technology Limited's headquarters?

They are based in Melbourne, Australia

How many employees does Bio-Gene Technology Limited have?

There are 1-10 employees working at Bio-Gene Technology Limited

What is Bio-Gene Technology Limited's website?

It is https://bio-gene.com.au/

What type of sector is Bio-Gene Technology Limited?

Bio-Gene Technology Limited is in the Healthcare sector

What type of industry is Bio-Gene Technology Limited?

Bio-Gene Technology Limited is in the Biotechnology industry

Who are Bio-Gene Technology Limited's peers and competitors?

The following five companies are Bio-Gene Technology Limited's industry peers:

- UroGen Pharma Ltd.

- Immunovant, Inc.

- Brainstorm Cell Therapeutics

- VBI Vaccines, Inc.

- Ocugen